Anirban Maitra

Anirban Maitra

Auto-generated profile, based on publicly available information

Anirban Maitra

Johns Hopkins University School of Medicine

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2007 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
SBSavita Bisht
Savita Bisht
GFGeorg Feldmann
Georg Feldmann
SSSheetal Soni
Sheetal Soni
RRRajani Ravi
Rajani Ravi
CKCollins Karikar
Collins Karikar
AMAnirban Maitra
Anirban Maitra
Background: Curcumin, a yellow polyphenol extracted from the rhizome of turmeric (Curcuma longa), has potent anti-cancer properties as demonstrated in a plethora of human cancer cell line and animal carcinogenesis models. Nevertheless, widespread clinical application of this relatively efficacious agent in cancer and other diseases has been limited due to poor aqueous solubility, and consequently, minimal systemic bioavailability. Nanoparticle-based drug delivery approaches have the potential for rendering hydrophobic agents like curcumin dispersible in aqueous media, thus circumventing the pitfalls of poor solubility.Results: We have synthesized polymeric nanoparticle encapsulated formulation of curcumin – nanocurcumin – utilizing the micellar aggregates of cross-linked and random copolymers of N-isopropylacrylamide (NIPAAM), with N-vinyl-2-pyrrolidone (VP) and poly(ethyleneglycol)monoacrylate (PEG-A). Physico-chemical characterization of the polymeric nanoparticles by dynamic laser light scattering and transmission electron microscopy confirms a narrow size distribution in the 50 nm range. Nanocurcumin, unlike free curcumin, is readily dispersed in aqueous media. Nanocurcumin demonstrates comparablein vitrotherapeutic efficacy to free curcumin against a panel of human pancreatic cancer cell lines, as assessed by cell viability and clonogenicity assays in soft agar. Further, nanocurcumin's mechanisms of action on pancreatic cancer cells mirror that of free curcumin, including induction of cellular apoptosis, blockade of nuclear factor kappa B (NFκB) activation, and downregulation of steady state levels of multiple pro-inflammatory cytokines (IL-6, IL-8, and TNFα).Conclusion: Nanocurcumin provides an opportunity to expand the clinical repertoire of this efficacious agent by enabling ready aqueous dispersion. Future studies utilizing nanocurcumin are warranted in pre-clinicalin vivomodels of cancer and other diseases that might benefit from the effects of curcumin.

2 December 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
NHNils Habbe
Nils Habbe
GSGuanglu Shi
Guanglu Shi
RMRobert A. Meguid
Robert A. Meguid
VFVolker Fendrich
Volker Fendrich
FEFarzad Esni
Farzad Esni
AMAnirban Maitra
Anirban Maitra
Pancreatic ductal adenocarcinoma (PDAC) is believed to arise through a multistep model comprised of putative precursor lesions known as pancreatic intraepithelial neoplasia (PanIN). Recent genetically engineered mouse models of PDAC demonstrate a comparable morphologic spectrum of murine PanIN (mPanIN) lesions. The histogenesis of PanIN and PDAC in both mice and men remains controversial. The most faithful genetic models activate an oncogenic Kras G12D knockin allele within the pdx1 - or ptf1a/p48 -expression domain of the entire pancreatic anlage during development, thus obscuring the putative cell(s)-of-origin from which subsequent mPanIN lesions arise. In our study, activation of this knockin Kras G12D allele in the Elastase - and Mist1 -expressing mature acinar compartment of adult mice resulted in the spontaneous induction of mPanIN lesions of all histological grades, although invasive carcinomas per se were not seen. We observed no requirement for concomitant chronic exocrine injury in the induction of mPanIN lesions from the mature acinar cell compartment. The acinar cell derivation of the mPanINs was established through lineage tracing in reporter mice, and by microdissection of lesional tissue demonstrating Cre -mediated recombination events. In contrast to the uniformly penetrant mPanIN phenotype observed following developmental activation of Kras G12D in the Pdx1 -expressing progenitor cells, the Pdx1 -expressing population in the mature pancreas (predominantly islet β cells) appears to be relatively resistant to the effects of oncogenic Kras . We conclude that in the appropriate genetic context, the differentiated acinar cell compartment in adult mice retains its susceptibility for spontaneous transformation into mPanIN lesions, a finding with potential relevance vis-à-vis the origins of PDAC.

1 September 2003 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
AMAnirban Maitra
Anirban Maitra
VAVolkan Adsay
Volkan Adsay
PAPedram Argani
Pedram Argani
CIChristine Iacobuzio-Donahue
Christine Iacobuzio-Donahue
AMAngelo De Marzo
Angelo De Marzo
RHRalph H Hruban
Ralph H Hruban

1 November 2002 in The American Journal of Pathology
Verified
Journal Article
Closed access
NHN. Tjarda van Heek
N. Tjarda van Heek
AMAlan K. Meeker
Alan K. Meeker
SKScott E. Kern
Scott E. Kern
CYCharles J. Yeo
Charles J. Yeo
KLKeith D. Lillemoe
Keith D. Lillemoe
AMAnirban Maitra
Anirban Maitra

15 February 2009 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
NHNils Habbe
Nils Habbe
JKJan-Bart M. Koorstra
Jan-Bart M. Koorstra
JMJoshua T. Mendell
Joshua T. Mendell
GOG. Johan Offerhaus
G. Johan Offerhaus
JRJi Kon Ryu
Ji Kon Ryu
AMAnirban Maitra
Anirban Maitra
Background: Intraductal papillary mucinous neoplasms (IPMNs) are non-invasive precursor lesions of pancreatic cancer. Misexpression of microRNAs (miRNAs) is commonly observed in pancreatic adenocar...

1 August 2011 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
DPDipankar Pramanik
Dipankar Pramanik
NCNathaniel R. Campbell
Nathaniel R. Campbell
CKCollins Karikari
Collins Karikari
RCRaghu Chivukula
Raghu Chivukula
OKOliver A. Kent
Oliver A. Kent
AMAnirban Maitra
Anirban Maitra
Mis-expression of microRNAs (miRNA) is widespread in human cancers, including in pancreatic cancer. Aberrations of miRNA include overexpression of oncogenic miRs (Onco-miRs) or downregulation of so-called tumor suppressor TSG-miRs. Restitution of TSG-miRs in cancer cells through systemic delivery is a promising avenue for pancreatic cancer therapy. We have synthesized a lipid-based nanoparticle for systemic delivery of miRNA expression vectors to cancer cells (nanovector). The plasmid DNA–complexed nanovector is approximately 100 nm in diameter and shows no apparent histopathologic or biochemical evidence of toxicity upon intravenous injection. Two miRNA candidates known to be downregulated in the majority of pancreatic cancers were selected for nanovector delivery: miR-34a, which is a component of the p53 transcriptional network and regulates cancer stem cell survival, and the miR-143/145 cluster, which together repress the expression of KRAS2 and its downstream effector Ras-responsive element binding protein-1 (RREB1). Systemic intravenous delivery with either miR-34a or miR-143/145 nanovectors inhibited the growth of MiaPaCa-2 subcutaneous xenografts (P < 0.01 for miR-34a; P < 0.05 for miR-143/145); the effects were even more pronounced in the orthotopic (intrapancreatic) setting (P < 0.0005 for either nanovector) when compared with vehicle or mock nanovector delivering an empty plasmid. Tumor growth inhibition was accompanied by increased apoptosis and decreased proliferation. The miRNA restitution was confirmed in treated xenografts by significant upregulation of the corresponding miRNA and significant decreases in specific miRNA targets (SIRT1, CD44 and aldehyde dehydrogenase for miR34a, and KRAS2 and RREB1 for miR-143/145). The nanovector is a platform with potential broad applicability in systemic miRNA delivery to cancer cells. Mol Cancer Ther; 10(8); 1470–80. ©2011 AACR.